Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:41 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
ACZ885 for the Treatment of Abdominal Aortic Aneurysm
NCT02007252 · Novartis Pharmaceuticals · PHASE2 · terminated · last registry update 2021-01-05 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The results of a third interim analysis (ad hoc) indicated a lack of efficacy and futility in continuing the trial.” | – | Registry record, Novartis Pharmaceuticals |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL1B within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-09-17Also stopped (terminated): Novartis Pharmaceuticals, AIN457 + ACZ885 (NCT01364389)
- 2021-08-16Results posted on the registry: Novartis Pharmaceuticals, Canakinumab + Placebo (NCT04362813)
- 2021-07-19Results posted on the registry: Novartis Pharmaceuticals, Canakinumab 150mg in prefilled syringe (NCT01431638)
- 2021-07-09Results posted on the registry: Novartis, Canakinumab (NCT00554606)
- 2021-07-09Results posted on the registry: Novartis Pharmaceuticals, ACZ885 + Triamcinolone acetonide 40 mg (NCT01470989)
- 2021-06-10Results posted on the registry: Novartis Pharmaceuticals, Canakinumab (NCT00770601)
- 2021-06-10Also stopped (terminated): Novartis Pharmaceuticals, Canakinumab (NCT00770601)
- 2021-06-09Results posted on the registry: Novartis Pharmaceuticals, Canakinumab (NCT00927810)
- 2021-04-15Results posted on the registry: The Cleveland Clinic, Canakinumab Injection 600mg + Canakinumab Injection 300mg (NCT04365153)
- 2021-01-22Phase 3 first posted: Novartis Pharmaceuticals, Canakinumab (NCT04717635)
- 2020-12-17Results posted on the registry: Novartis Pharmaceuticals, ACZ885 + Placebo (NCT02961218)
- 2020-08-12Phase 3 first posted: University Hospital, Basel, Switzerland, Canakinumab + Placebo (NCT04510493)
- 2020-08-07Results posted on the registry: Charite University, Berlin, Germany, Canakinumab + Placebo (NCT02204293)
- 2020-08-07Also stopped (terminated): Charite University, Berlin, Germany, Canakinumab + Placebo (NCT02204293)
- 2020-06-11Results posted on the registry: Novartis Pharmaceuticals, Canakinumab (NCT02756650)
- 2020-05-19Results posted on the registry: Novartis Pharmaceuticals, canakinumab (NCT02334748)
- 2020-04-27Phase 3 first posted: Novartis Pharmaceuticals, Canakinumab + Placebo (NCT04362813)
- 2020-03-16Results posted on the registry: Novartis Pharmaceuticals, ACZ885 + Placebo (NCT02888080)
- 2020-01-22Results posted on the registry: Novartis Pharmaceuticals, Canakinumab + Placebo (NCT01327846)
- 2020-01-14Phase 3 first posted: Pancreatic Cancer Action Network, Gemcitabine combined with nab-paclitaxel + Dose -mFOLFIRINOX (NCT04229004)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision